74
Total Publications
2,522
Total Citations
Top Researchers
- Vladimir Vladimirov 4,462 citations • 52 papers
- Karina V. Martirosyan 187 citations • 27 papers
- Murat Murzabekov 135 citations • 13 papers
- D.V. Shchitov 106 citations • 21 papers
- Daria V. Saenko 90 citations • 7 papers
- Sergey Polenkov 81 citations • 4 papers
- Ilya Safonov 73 citations • 3 papers
- Beka Samkharadze 73 citations • 3 papers
- Vladmir Vladmirov 61 citations • 1 papers
- V.N. Orobinskaya 47 citations • 49 papers
Most Cited Papers
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study 2011 • 1,087 citations
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 2020 • 637 citations
- Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study 2016 • 84 citations
- Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer 2014 • 79 citations
- Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens 2019 • 72 citations
- A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type <i>KRAS</i> who have received first‐line systemic therapy 2016 • 68 citations
- Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial 2024 • 68 citations
- Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial 2023 • 61 citations
- Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) 2024 • 59 citations
- PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study 2019 • 55 citations